Theravance Biopharma

Sells Yupelri, an inhaled medicine for the lung disease COPD.

Sold all

What the manager says

In short: Bought in Q1 after a failed trial; company agreed to sell near the low end of the manager’s value range.

Named in

Q2 2026 letter

Owned by

None of the funds we follow

More about Theravance Biopharma

This fund doesn’t file the government report, so share counts aren’t public.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works